In silico identification of milk antihypertensive di- and tripeptides involved in angiotensin I–converting enzyme inhibitory activity

Nutrition Research

Volumn 46, Issue , 2017, Pages 22-30

  Vukic, Vladimir R ^a   Vukic, Dajana V ^a   Milanovic, Spasenija D ^a   Ilicic, Mirela D ^a   Kanuric, Katarina G ^a   Johnson, Mark S ^b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

3D QSAR; Angiotensin converting enzyme; Milk; Molecular docking; Peptides

Indexed keywords

DIPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MILK PROTEIN; TRIPEPTIDE; ACE PROTEIN, HUMAN; ANTIHYPERTENSIVE AGENT; OLIGOPEPTIDE; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; ENZYME ACTIVE SITE; FUNCTIONAL FOOD; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; BIOLOGY; BOVINE; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; DIETARY SUPPLEMENT; EXPERT SYSTEM; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DEGRADATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING SITES; CATALYTIC DOMAIN; CATTLE; COMPUTATIONAL BIOLOGY; DIETARY SUPPLEMENTS; DIPEPTIDES; EXPERT SYSTEMS; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MILK PROTEINS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTEIN CONFORMATION; PROTEOLYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85028056248     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2017.07.009     Document Type: Article

References (42)

1. Kotchen, T.A., Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 23 (2010), 1170–1178.
2. Rawlings, N.D., Barrett, A.J., Evolutionary families of peptidases. Biochem J 290:Pt 1 (1993), 205–218.
3. Fuchs, S., Xiao, H.D., Hubert, C., Michaud, A., Campbell, D.J., Adams, J.W., et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51 (2008), 267–274.
4. van Esch, J.H., Tom, B., Dive, V., Batenburg, W.W., Georgiadis, D., Yiotakis, A., et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I–induced vasoconstriction. Hypertension 45 (2005), 120–125.
5. Coates, D., The angiotensin converting enzyme (ACE). Int J Biochem Cell Biol 35 (2003), 769–773.
6. Lew, R.A., The zinc metallopeptidase family: new facts, new functions. Protein Pept Lett 11 (2004), 407–414.
7. Acharya, K.R., Sturrock, E.D., Riordan, J.F., Ehlers, M.R., ACE revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2 (2003), 891–902.
8. Natesh, R., Schwager, S.L., Sturrock, E.D., Acharya, K.R., Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421 (2003), 551–554.
9. Masuyer, G., Schwager, S.L., Sturrock, E.D., Isaac, R.E., Acharya, K.R., Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci Rep, 2, 2012, 717.
10. Soffer, R.L., Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu Rev Biochem 45 (1976), 73–94.
11. Cheung, H.S., Cushman, D.W., Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Biophys Acta (BBA) - Enzymology 293 (1973), 451–463.
12. Cushman, D.W., Pluščec, J., Williams, N.J., Weaver, E.R., Sabo, E.F., Kocy, O., et al. Inhibition of angiotensin-converting enzyme by analogs of peptides from Bothrops jararaca venom. Experientia 29 (1973), 1032–1035.
13. Erdös, E.G., The ACE and I: how ACE inhibitors came to be. FASEB J 20 (2006), 1034–1038.
14. Jaspard, E., Wei, L., Alhenc-Gelas, F., Differences in the properties and enzymatic specificities of the two active sites of angiotensin I–converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268 (1993), 9496–9503.
15. Corradi, H.R., Chitapi, I., Sewell, B.T., Georgiadis, D., Dive, V., Sturrock, E.D., et al. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46 (2007), 5473–5478.
16. Kroger, W.L., Douglas, R.G., O'Neill, H.G., Dive, V., Sturrock, E.D., Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 48 (2009), 8405–8412.
17. FritzGerald, R., Murray, B., Walsh, D., Hypotensive peptides from milk proteins. J Nutr 134 (2004), 980S–988S.
18. Iwaniak, A., Dziuba, J., Animal and plant origin proteins as the precursors of peptides with ACE inhibitory activity. Proteins evaluation by means of in silico methods. Food Technol Biotechnol 47 (2009), 441–449.
19. Iwaniak, A., Minkiewicz, P., Darewicz, M., Food-originating ACE inhibitors, including antihypertensive peptides, as preventive food components in blood pressure reduction. Compr Rev Food Sci Food Saf 13 (2014), 114–134.
20. Pripp, A.H., Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food Nutr Res, 52, 2008.
21. Tidona, F., Criscione, A., Guastella, A.M., Zuccaro, A., Bordonaro, S., Marletta, D., Bioactive peptides in dairy products. Ital J Anim Sci 8 (2009), 315–340.
22. Li, G.-H., Le, G.-W., Shi, Y.-H., Shrestha, S., Angiotensin I–converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr Res 24 (2004), 469–486.
23. Hernández-Ledesma, B., Ramos, M., Recio, I., Amigo, L., Effect of beta-lactoglobulin hydrolysis with thermolysin under denaturing temperatures on the release of bioactive peptides. J Chromatogr A 1116 (2006), 31–37.
24. Cherkasov, A., Muratov, E.N., Fourches, D., Varnek, A., Baskin, I.I., Cronin, M., et al. QSAR modeling: where have you been? Where are you going to?. J Med Chem 57 (2014), 4977–5010.
25. Murumkar, P.R., Shinde, A.C., Sharma, M.K., Yamaguchi, H., Miniyar, P.B., Yadav, M.R., Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors. SAR QSAR Environ Res 27 (2016), 265–292.
26. Minkiewicz, P., Dziuba, J., Iwaniak, A., Dziuba, M., Darewicz, M., BIOPEP database and other programs for processing bioactive peptide sequences. J AOAC Int 91 (2008), 965–980.
27. O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., Open babel: an open chemical toolbox. J Chem, 3, 2011, 33.
28. Halgren, T.A., Nachbar, R.B., Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comput Chem 17 (1996), 587–615.
29. Caballero, J., Saavedra, M., Fernández, M., González-Nilo, F.D., Quantitative structure-activity relationship of rubiscolin analogues as δ opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). J Agric Food Chem 55 (2007), 8101–8104.
30. Jain, A.N., Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46 (2003), 499–511.
31. Cramer, R.D., The inevitable QSAR renaissance. J Comput Aided Mol Des 26 (2012), 35–38.
32. Klebe, G., Abraham, U., Mietzner, T., Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37 (1994), 4130–4146.
33. Klebe, G., Abraham, U., Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J Comput Aided Mol Des 13 (1999), 1–10.
34. Cramer, R.D., Patterson, D.E., Bunce, J.D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 (1988), 5959–5967.
35. Bush, B.L., Nachbar, R.B., Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7 (1993), 587–619.
36. Tetko, I.V., Tanchuk, V.Y., Villa, A.E., Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci 41 (2001), 1407–1421.
37. Khedr, S., Deussen, A., Kopaliani, I., Zatschler, B., Martin, M., Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo. Eur J Nutr, 2017.
38. Potshangbam, A.M., Tanneeru, K., Reddy, B.M., Guruprasad, L., 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3. Bioorg Med Chem Lett 21 (2011), 7219–7223.
39. Yang, C.Y., Dantzig, A.H., Pidgeon, C., Intestinal peptide transport systems and oral drug availability. Pharm Res 16 (1999), 1331–1343.
40. Satake, M., Enjoh, M., Nakamura, Y., Takano, T., Kawamura, Y., Arai, S., et al. Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci Biotechnol Biochem 66 (2002), 378–384.
41. Masuda, O., Nakamura, Y., Takano, T., Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 126 (1996), 3063–3068.
42. Charman, W.N., Porter, C.J.H., Mithani, S., Dressman, J.B., Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86 (1997), 269–282.